Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly…